Mutation of ERBB2 Provides a Novel Alternative Mechanism for the Ubiquitous Activation of RAS-MAPK in Ovarian Serous Low Malignant Potential TumorsMichael S. Anglesio, David D.L. Bowtell, Richard W. Tothill et al.|Molecular Cancer Research|2008Cited by 130
Genomic Classification of Serous Ovarian Cancer with Adjacent Borderline Differentiates RAS Pathway and <i>TP53</i> -Mutant Tumors and Identifies <i>NRAS</i> as an Oncogenic DriverCatherine Emmanuel, Anna DeFazio, Yoke-Eng Chiew et al.|Clinical Cancer Research|2014Cited by 119